LGALS3 and cardiovascular disorder: Furthermore, serum galectin-3 should be assessed in conjunction with both traditional risk factors and novel biomarkers, aiming to construct combined models that would enable effective stratification of hemodialysis patients in regards to cardiovascular disease and mortality risk.